

U.S.S.N. 09/625,963

Filed: July 26, 2000

AMENDMENT AND RESPONSE TO OFFICE ACTION

In the Claims

1. (previously presented) A peptide derived from the amino acid sequence of human WT-1 polypeptide having at least 9 but fewer than 100 amino acids, wherein the peptide contains the amino acid sequence RMFPNAPYL (SEQ ID NO:1), wherein the peptide is processed by HLA-A0201-positive antigen presenting cells (APC) to produce the HLA-A0201 bound RMFPNAPYL (SEQ ID NO:1) sequence.

Claims 2-4 (cancelled).

5. (previously presented) A peptide according to claim 1 wherein the peptide is processed by HLA-A0201-positive antigen presenting cells (APC) to produce the sequence RMFPNAPYL (SEQ ID NO:1) that is capable of eliciting the production of a cytotoxic lymphocyte (CTL), wherein the CTL recognizes a HLA-AA0201-positive cell which aberrantly expresses intact human WT-1 protein.

Claim 6 (cancelled).

7. (previously presented) A peptide according to claim 1 consisting of the amino acid sequence RMFPNAPYL (SEQ ID NO:1).

Claims 8-14 (cancelled).

15. (previously presented) A pharmaceutical composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier.

Claims 16-18 (cancelled).

19. (currently amended) A vaccine for a tumor cell in which HLA-A0201 is expressed and WT-1 is over-expressed, the vaccine comprising a peptide according to claim 1.

Claims 20-48 (cancelled).